Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, Ziv M, Pinter A, Vender R, Hugot S, You R, Milutinovic M, Thaçi D. Blauvelt A, et al. Among authors: vanaclocha f. J Am Acad Dermatol. 2017 Jan;76(1):60-69.e9. doi: 10.1016/j.jaad.2016.08.008. Epub 2016 Sep 20. J Am Acad Dermatol. 2017. PMID: 27663079 Clinical Trial.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M. Thaçi D, et al. Among authors: vanaclocha f. J Am Acad Dermatol. 2015 Sep;73(3):400-9. doi: 10.1016/j.jaad.2015.05.013. Epub 2015 Jun 17. J Am Acad Dermatol. 2015. PMID: 26092291 Free article. Clinical Trial.
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
Blauvelt A, Reich K, Mehlis S, Vanaclocha F, Sofen H, Abramovits W, Zhao Y, Gilloteau I, Davenport E, Williams N, Guana A, Tyring S. Blauvelt A, et al. Among authors: vanaclocha f. J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1693-1699. doi: 10.1111/jdv.14391. Epub 2017 Aug 8. J Eur Acad Dermatol Venereol. 2017. PMID: 28602039 Free PMC article. Clinical Trial.
Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study.
Daudén E, Pujol RM, Sánchez-Carazo JL, Toribio J, Vanaclocha F, Puig L, Yébenes M, Sabater E, Casado MA, Caloto MT, Aragón B; VACAP Study Investigators. Daudén E, et al. Among authors: vanaclocha f. Actas Dermosifiliogr. 2013 Nov;104(9):807-14. doi: 10.1016/j.ad.2013.03.005. Epub 2013 Jul 1. Actas Dermosifiliogr. 2013. PMID: 23827342 Free article.
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis.
Dávila-Seijo P, Dauden E, Carretero G, Ferrandiz C, Vanaclocha F, Gómez-García FJ, Herrera-Ceballos E, De la Cueva-Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina M, López-Estebaranz JL, Ferrán M, Torrado R, Carrascosa JM, Llamas M, Rivera R, Jiménez-Puya R, García-Doval I; BIOBADADERM Study Group. Dávila-Seijo P, et al. Among authors: vanaclocha f. J Eur Acad Dermatol Venereol. 2016 Nov;30(11):1942-1950. doi: 10.1111/jdv.13682. Epub 2016 Jun 22. J Eur Acad Dermatol Venereol. 2016. PMID: 27329511
Cryptococcal cellulitis in an immunocompetent host.
Sanchez-Albisua B, Rodriguez-Peralto JL, Romero G, Alonso J, Vanaclocha F, Iglesias L. Sanchez-Albisua B, et al. Among authors: vanaclocha f. J Am Acad Dermatol. 1997 Jan;36(1):109-12. doi: 10.1016/s0190-9622(97)70340-2. J Am Acad Dermatol. 1997. PMID: 8996275 No abstract available.
Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry.
Medina C, Carretero G, Ferrandiz C, Dauden E, Vanaclocha F, Gómez-García FJ, Herrera-Ceballos E, De la Cueva-Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina M, López-Estebaranz JL, Ferrán M, Carrascosa JM, Torrado R, Argila D, Rivera R, Jiménez-Puya R, García-Doval I; BIOBADADERM Study Group. Medina C, et al. Among authors: vanaclocha f. J Eur Acad Dermatol Venereol. 2015 May;29(5):858-64. doi: 10.1111/jdv.12688. Epub 2014 Sep 3. J Eur Acad Dermatol Venereol. 2015. PMID: 25185962
Febrile ulceronecrotic Mucha-Habermann disease.
López-Estebaranz JL, Vanaclocha F, Gil R, García B, Iglesias L. López-Estebaranz JL, et al. Among authors: vanaclocha f. J Am Acad Dermatol. 1993 Nov;29(5 Pt 2):903-6. doi: 10.1016/0190-9622(93)70267-w. J Am Acad Dermatol. 1993. PMID: 8408838 Review.
120 results